The effect of using albumin-perfluorohexane/cisplatin-magnetite nanoparticles produced by hydrothermal method against gastric cancer cells through combination therapy

Because magnetic nanoparticles (NPs) have the ability to combine different therapies such as drug delivery and photothermal therapy (PTT) along with reducing cancer drug resistance, their use in cancer treatment is considerable. For this purpose, we developed albumin-perfluorohexane/cisplatin-magnet...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Dongsheng Li [verfasserIn] Yue Fan [verfasserIn] Miaomiao Liu [verfasserIn] SiLin Huang [verfasserIn] Shasha Wang [verfasserIn]

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2023

Schlagwörter:	Gastric cancer Photothermal therapy Chemotherapy Magnetic nanoparticle Cisplatin

Übergeordnetes Werk:	In: Arabian Journal of Chemistry - Elsevier, 2016, 16(2023), 7, Seite 104758-
Übergeordnetes Werk:	volume:16 ; year:2023 ; number:7 ; pages:104758-

Links:	Link aufrufen Link aufrufen Link aufrufen Journal toc

DOI / URN:	10.1016/j.arabjc.2023.104758

Katalog-ID:	DOAJ089103653

Internformat


LEADER	01000naa a22002652 4500
001	DOAJ089103653
003	DE-627
005	20230505021248.0
007	cr uuu---uuuuu
008	230505s2023 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.1016/j.arabjc.2023.104758 \|2 doi
035			\|a (DE-627)DOAJ089103653
035			\|a (DE-599)DOAJ1891e51adc65479380b68163483747a6
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
050		0	\|a QD1-999
100	0		\|a Dongsheng Li \|e verfasserin \|4 aut
245	1	4	\|a The effect of using albumin-perfluorohexane/cisplatin-magnetite nanoparticles produced by hydrothermal method against gastric cancer cells through combination therapy
264		1	\|c 2023
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a Because magnetic nanoparticles (NPs) have the ability to combine different therapies such as drug delivery and photothermal therapy (PTT) along with reducing cancer drug resistance, their use in cancer treatment is considerable. For this purpose, we developed albumin-perfluorohexane/cisplatin-magnetite NPs (A-PFH/C-MNPs) by hydrothermal method. Then, the physicochemical properties of the MNPs and A-PFH/C-MNPs were investigated by SEM, TEM, XRD, and FTIR. In the following, drug release at different pH and A-PFH/C-MNPs thermal reactions were assessed. The toxicity of different drug formulations against advanced gastric cancer (AGS) and mouse fibroblast (3 T3) cells were assessed by MTT assay, followed by flow cytometry and real time PCR on AGS cells. The results determined that A-PFH/C-MNPs (∼142 nm) with a relatively uniform distribution, in addition to increasing the loading capacity up to 60%, raise the PFH release by increasing the temperature from 37 °C to 45 °C. Also, in vitro outcomes exhibited higher toxicity of A-PFH/C-MNPs + PTT compared to free C against AGS cells. Whereas, the toxicity of A-C-MNPs and A-PFH/C-MNPs + PTT on 3 T3 cells as normal cells was much lower compared to the cancer cells. The mechanism of cytotoxicity indicates that A-PFH/C-MNPs + PTT significantly increase apoptosis by inducing expression of TNF-α and Bax mRNA compared to A-C-MNPs. Overall, A-PFH/C-MNPs + PTT provided a promising platform in anticancer activity by increasing drug loading capacity and combined chemotherapy and PTT.
650		4	\|a Gastric cancer
650		4	\|a Photothermal therapy
650		4	\|a Chemotherapy
650		4	\|a Magnetic nanoparticle
650		4	\|a Cisplatin
653		0	\|a Chemistry
700	0		\|a Yue Fan \|e verfasserin \|4 aut
700	0		\|a Miaomiao Liu \|e verfasserin \|4 aut
700	0		\|a SiLin Huang \|e verfasserin \|4 aut
700	0		\|a Shasha Wang \|e verfasserin \|4 aut
773	0	8	\|i In \|t Arabian Journal of Chemistry \|d Elsevier, 2016 \|g 16(2023), 7, Seite 104758- \|w (DE-627)609401564 \|w (DE-600)2515214-2 \|x 18785352 \|7 nnns
773	1	8	\|g volume:16 \|g year:2023 \|g number:7 \|g pages:104758-
856	4	0	\|u https://doi.org/10.1016/j.arabjc.2023.104758 \|z kostenfrei
856	4	0	\|u https://doaj.org/article/1891e51adc65479380b68163483747a6 \|z kostenfrei
856	4	0	\|u http://www.sciencedirect.com/science/article/pii/S1878535223002204 \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/1878-5352 \|y Journal toc \|z kostenfrei
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_DOAJ
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_31
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_70
912			\|a GBV_ILN_73
912			\|a GBV_ILN_95
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_151
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_213
912			\|a GBV_ILN_224
912			\|a GBV_ILN_230
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_602
912			\|a GBV_ILN_2001
912			\|a GBV_ILN_2003
912			\|a GBV_ILN_2004
912			\|a GBV_ILN_2005
912			\|a GBV_ILN_2006
912			\|a GBV_ILN_2007
912			\|a GBV_ILN_2008
912			\|a GBV_ILN_2009
912			\|a GBV_ILN_2010
912			\|a GBV_ILN_2011
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_2015
912			\|a GBV_ILN_2020
912			\|a GBV_ILN_2021
912			\|a GBV_ILN_2025
912			\|a GBV_ILN_2026
912			\|a GBV_ILN_2027
912			\|a GBV_ILN_2034
912			\|a GBV_ILN_2038
912			\|a GBV_ILN_2044
912			\|a GBV_ILN_2048
912			\|a GBV_ILN_2049
912			\|a GBV_ILN_2050
912			\|a GBV_ILN_2055
912			\|a GBV_ILN_2056
912			\|a GBV_ILN_2059
912			\|a GBV_ILN_2061
912			\|a GBV_ILN_2064
912			\|a GBV_ILN_2088
912			\|a GBV_ILN_2106
912			\|a GBV_ILN_2110
912			\|a GBV_ILN_2112
912			\|a GBV_ILN_2122
912			\|a GBV_ILN_2129
912			\|a GBV_ILN_2143
912			\|a GBV_ILN_2152
912			\|a GBV_ILN_2153
912			\|a GBV_ILN_2190
912			\|a GBV_ILN_2232
912			\|a GBV_ILN_2470
912			\|a GBV_ILN_2507
912			\|a GBV_ILN_4012
912			\|a GBV_ILN_4035
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4242
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4251
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4326
912			\|a GBV_ILN_4333
912			\|a GBV_ILN_4334
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4367
912			\|a GBV_ILN_4393
912			\|a GBV_ILN_4700
951			\|a AR
952			\|d 16 \|j 2023 \|e 7 \|h 104758-

Indexfelder

author_variant	d l dl y f yf m l ml s h sh s w sw
matchkey_str	article:18785352:2023----::hefcouigluiprlooeaeipaimgeieaoatcepouebhdohramtoaantat
hierarchy_sort_str	2023
callnumber-subject-code	QD
publishDate	2023
allfields	10.1016/j.arabjc.2023.104758 doi (DE-627)DOAJ089103653 (DE-599)DOAJ1891e51adc65479380b68163483747a6 DE-627 ger DE-627 rakwb eng QD1-999 Dongsheng Li verfasserin aut The effect of using albumin-perfluorohexane/cisplatin-magnetite nanoparticles produced by hydrothermal method against gastric cancer cells through combination therapy 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Because magnetic nanoparticles (NPs) have the ability to combine different therapies such as drug delivery and photothermal therapy (PTT) along with reducing cancer drug resistance, their use in cancer treatment is considerable. For this purpose, we developed albumin-perfluorohexane/cisplatin-magnetite NPs (A-PFH/C-MNPs) by hydrothermal method. Then, the physicochemical properties of the MNPs and A-PFH/C-MNPs were investigated by SEM, TEM, XRD, and FTIR. In the following, drug release at different pH and A-PFH/C-MNPs thermal reactions were assessed. The toxicity of different drug formulations against advanced gastric cancer (AGS) and mouse fibroblast (3 T3) cells were assessed by MTT assay, followed by flow cytometry and real time PCR on AGS cells. The results determined that A-PFH/C-MNPs (∼142 nm) with a relatively uniform distribution, in addition to increasing the loading capacity up to 60%, raise the PFH release by increasing the temperature from 37 °C to 45 °C. Also, in vitro outcomes exhibited higher toxicity of A-PFH/C-MNPs + PTT compared to free C against AGS cells. Whereas, the toxicity of A-C-MNPs and A-PFH/C-MNPs + PTT on 3 T3 cells as normal cells was much lower compared to the cancer cells. The mechanism of cytotoxicity indicates that A-PFH/C-MNPs + PTT significantly increase apoptosis by inducing expression of TNF-α and Bax mRNA compared to A-C-MNPs. Overall, A-PFH/C-MNPs + PTT provided a promising platform in anticancer activity by increasing drug loading capacity and combined chemotherapy and PTT. Gastric cancer Photothermal therapy Chemotherapy Magnetic nanoparticle Cisplatin Chemistry Yue Fan verfasserin aut Miaomiao Liu verfasserin aut SiLin Huang verfasserin aut Shasha Wang verfasserin aut In Arabian Journal of Chemistry Elsevier, 2016 16(2023), 7, Seite 104758- (DE-627)609401564 (DE-600)2515214-2 18785352 nnns volume:16 year:2023 number:7 pages:104758- https://doi.org/10.1016/j.arabjc.2023.104758 kostenfrei https://doaj.org/article/1891e51adc65479380b68163483747a6 kostenfrei http://www.sciencedirect.com/science/article/pii/S1878535223002204 kostenfrei https://doaj.org/toc/1878-5352 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2034 GBV_ILN_2038 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2088 GBV_ILN_2106 GBV_ILN_2110 GBV_ILN_2112 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2190 GBV_ILN_2232 GBV_ILN_2470 GBV_ILN_2507 GBV_ILN_4012 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4393 GBV_ILN_4700 AR 16 2023 7 104758-
spelling	10.1016/j.arabjc.2023.104758 doi (DE-627)DOAJ089103653 (DE-599)DOAJ1891e51adc65479380b68163483747a6 DE-627 ger DE-627 rakwb eng QD1-999 Dongsheng Li verfasserin aut The effect of using albumin-perfluorohexane/cisplatin-magnetite nanoparticles produced by hydrothermal method against gastric cancer cells through combination therapy 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Because magnetic nanoparticles (NPs) have the ability to combine different therapies such as drug delivery and photothermal therapy (PTT) along with reducing cancer drug resistance, their use in cancer treatment is considerable. For this purpose, we developed albumin-perfluorohexane/cisplatin-magnetite NPs (A-PFH/C-MNPs) by hydrothermal method. Then, the physicochemical properties of the MNPs and A-PFH/C-MNPs were investigated by SEM, TEM, XRD, and FTIR. In the following, drug release at different pH and A-PFH/C-MNPs thermal reactions were assessed. The toxicity of different drug formulations against advanced gastric cancer (AGS) and mouse fibroblast (3 T3) cells were assessed by MTT assay, followed by flow cytometry and real time PCR on AGS cells. The results determined that A-PFH/C-MNPs (∼142 nm) with a relatively uniform distribution, in addition to increasing the loading capacity up to 60%, raise the PFH release by increasing the temperature from 37 °C to 45 °C. Also, in vitro outcomes exhibited higher toxicity of A-PFH/C-MNPs + PTT compared to free C against AGS cells. Whereas, the toxicity of A-C-MNPs and A-PFH/C-MNPs + PTT on 3 T3 cells as normal cells was much lower compared to the cancer cells. The mechanism of cytotoxicity indicates that A-PFH/C-MNPs + PTT significantly increase apoptosis by inducing expression of TNF-α and Bax mRNA compared to A-C-MNPs. Overall, A-PFH/C-MNPs + PTT provided a promising platform in anticancer activity by increasing drug loading capacity and combined chemotherapy and PTT. Gastric cancer Photothermal therapy Chemotherapy Magnetic nanoparticle Cisplatin Chemistry Yue Fan verfasserin aut Miaomiao Liu verfasserin aut SiLin Huang verfasserin aut Shasha Wang verfasserin aut In Arabian Journal of Chemistry Elsevier, 2016 16(2023), 7, Seite 104758- (DE-627)609401564 (DE-600)2515214-2 18785352 nnns volume:16 year:2023 number:7 pages:104758- https://doi.org/10.1016/j.arabjc.2023.104758 kostenfrei https://doaj.org/article/1891e51adc65479380b68163483747a6 kostenfrei http://www.sciencedirect.com/science/article/pii/S1878535223002204 kostenfrei https://doaj.org/toc/1878-5352 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2034 GBV_ILN_2038 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2088 GBV_ILN_2106 GBV_ILN_2110 GBV_ILN_2112 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2190 GBV_ILN_2232 GBV_ILN_2470 GBV_ILN_2507 GBV_ILN_4012 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4393 GBV_ILN_4700 AR 16 2023 7 104758-
allfields_unstemmed	10.1016/j.arabjc.2023.104758 doi (DE-627)DOAJ089103653 (DE-599)DOAJ1891e51adc65479380b68163483747a6 DE-627 ger DE-627 rakwb eng QD1-999 Dongsheng Li verfasserin aut The effect of using albumin-perfluorohexane/cisplatin-magnetite nanoparticles produced by hydrothermal method against gastric cancer cells through combination therapy 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Because magnetic nanoparticles (NPs) have the ability to combine different therapies such as drug delivery and photothermal therapy (PTT) along with reducing cancer drug resistance, their use in cancer treatment is considerable. For this purpose, we developed albumin-perfluorohexane/cisplatin-magnetite NPs (A-PFH/C-MNPs) by hydrothermal method. Then, the physicochemical properties of the MNPs and A-PFH/C-MNPs were investigated by SEM, TEM, XRD, and FTIR. In the following, drug release at different pH and A-PFH/C-MNPs thermal reactions were assessed. The toxicity of different drug formulations against advanced gastric cancer (AGS) and mouse fibroblast (3 T3) cells were assessed by MTT assay, followed by flow cytometry and real time PCR on AGS cells. The results determined that A-PFH/C-MNPs (∼142 nm) with a relatively uniform distribution, in addition to increasing the loading capacity up to 60%, raise the PFH release by increasing the temperature from 37 °C to 45 °C. Also, in vitro outcomes exhibited higher toxicity of A-PFH/C-MNPs + PTT compared to free C against AGS cells. Whereas, the toxicity of A-C-MNPs and A-PFH/C-MNPs + PTT on 3 T3 cells as normal cells was much lower compared to the cancer cells. The mechanism of cytotoxicity indicates that A-PFH/C-MNPs + PTT significantly increase apoptosis by inducing expression of TNF-α and Bax mRNA compared to A-C-MNPs. Overall, A-PFH/C-MNPs + PTT provided a promising platform in anticancer activity by increasing drug loading capacity and combined chemotherapy and PTT. Gastric cancer Photothermal therapy Chemotherapy Magnetic nanoparticle Cisplatin Chemistry Yue Fan verfasserin aut Miaomiao Liu verfasserin aut SiLin Huang verfasserin aut Shasha Wang verfasserin aut In Arabian Journal of Chemistry Elsevier, 2016 16(2023), 7, Seite 104758- (DE-627)609401564 (DE-600)2515214-2 18785352 nnns volume:16 year:2023 number:7 pages:104758- https://doi.org/10.1016/j.arabjc.2023.104758 kostenfrei https://doaj.org/article/1891e51adc65479380b68163483747a6 kostenfrei http://www.sciencedirect.com/science/article/pii/S1878535223002204 kostenfrei https://doaj.org/toc/1878-5352 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2034 GBV_ILN_2038 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2088 GBV_ILN_2106 GBV_ILN_2110 GBV_ILN_2112 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2190 GBV_ILN_2232 GBV_ILN_2470 GBV_ILN_2507 GBV_ILN_4012 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4393 GBV_ILN_4700 AR 16 2023 7 104758-
allfieldsGer	10.1016/j.arabjc.2023.104758 doi (DE-627)DOAJ089103653 (DE-599)DOAJ1891e51adc65479380b68163483747a6 DE-627 ger DE-627 rakwb eng QD1-999 Dongsheng Li verfasserin aut The effect of using albumin-perfluorohexane/cisplatin-magnetite nanoparticles produced by hydrothermal method against gastric cancer cells through combination therapy 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Because magnetic nanoparticles (NPs) have the ability to combine different therapies such as drug delivery and photothermal therapy (PTT) along with reducing cancer drug resistance, their use in cancer treatment is considerable. For this purpose, we developed albumin-perfluorohexane/cisplatin-magnetite NPs (A-PFH/C-MNPs) by hydrothermal method. Then, the physicochemical properties of the MNPs and A-PFH/C-MNPs were investigated by SEM, TEM, XRD, and FTIR. In the following, drug release at different pH and A-PFH/C-MNPs thermal reactions were assessed. The toxicity of different drug formulations against advanced gastric cancer (AGS) and mouse fibroblast (3 T3) cells were assessed by MTT assay, followed by flow cytometry and real time PCR on AGS cells. The results determined that A-PFH/C-MNPs (∼142 nm) with a relatively uniform distribution, in addition to increasing the loading capacity up to 60%, raise the PFH release by increasing the temperature from 37 °C to 45 °C. Also, in vitro outcomes exhibited higher toxicity of A-PFH/C-MNPs + PTT compared to free C against AGS cells. Whereas, the toxicity of A-C-MNPs and A-PFH/C-MNPs + PTT on 3 T3 cells as normal cells was much lower compared to the cancer cells. The mechanism of cytotoxicity indicates that A-PFH/C-MNPs + PTT significantly increase apoptosis by inducing expression of TNF-α and Bax mRNA compared to A-C-MNPs. Overall, A-PFH/C-MNPs + PTT provided a promising platform in anticancer activity by increasing drug loading capacity and combined chemotherapy and PTT. Gastric cancer Photothermal therapy Chemotherapy Magnetic nanoparticle Cisplatin Chemistry Yue Fan verfasserin aut Miaomiao Liu verfasserin aut SiLin Huang verfasserin aut Shasha Wang verfasserin aut In Arabian Journal of Chemistry Elsevier, 2016 16(2023), 7, Seite 104758- (DE-627)609401564 (DE-600)2515214-2 18785352 nnns volume:16 year:2023 number:7 pages:104758- https://doi.org/10.1016/j.arabjc.2023.104758 kostenfrei https://doaj.org/article/1891e51adc65479380b68163483747a6 kostenfrei http://www.sciencedirect.com/science/article/pii/S1878535223002204 kostenfrei https://doaj.org/toc/1878-5352 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2034 GBV_ILN_2038 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2088 GBV_ILN_2106 GBV_ILN_2110 GBV_ILN_2112 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2190 GBV_ILN_2232 GBV_ILN_2470 GBV_ILN_2507 GBV_ILN_4012 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4393 GBV_ILN_4700 AR 16 2023 7 104758-
allfieldsSound	10.1016/j.arabjc.2023.104758 doi (DE-627)DOAJ089103653 (DE-599)DOAJ1891e51adc65479380b68163483747a6 DE-627 ger DE-627 rakwb eng QD1-999 Dongsheng Li verfasserin aut The effect of using albumin-perfluorohexane/cisplatin-magnetite nanoparticles produced by hydrothermal method against gastric cancer cells through combination therapy 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Because magnetic nanoparticles (NPs) have the ability to combine different therapies such as drug delivery and photothermal therapy (PTT) along with reducing cancer drug resistance, their use in cancer treatment is considerable. For this purpose, we developed albumin-perfluorohexane/cisplatin-magnetite NPs (A-PFH/C-MNPs) by hydrothermal method. Then, the physicochemical properties of the MNPs and A-PFH/C-MNPs were investigated by SEM, TEM, XRD, and FTIR. In the following, drug release at different pH and A-PFH/C-MNPs thermal reactions were assessed. The toxicity of different drug formulations against advanced gastric cancer (AGS) and mouse fibroblast (3 T3) cells were assessed by MTT assay, followed by flow cytometry and real time PCR on AGS cells. The results determined that A-PFH/C-MNPs (∼142 nm) with a relatively uniform distribution, in addition to increasing the loading capacity up to 60%, raise the PFH release by increasing the temperature from 37 °C to 45 °C. Also, in vitro outcomes exhibited higher toxicity of A-PFH/C-MNPs + PTT compared to free C against AGS cells. Whereas, the toxicity of A-C-MNPs and A-PFH/C-MNPs + PTT on 3 T3 cells as normal cells was much lower compared to the cancer cells. The mechanism of cytotoxicity indicates that A-PFH/C-MNPs + PTT significantly increase apoptosis by inducing expression of TNF-α and Bax mRNA compared to A-C-MNPs. Overall, A-PFH/C-MNPs + PTT provided a promising platform in anticancer activity by increasing drug loading capacity and combined chemotherapy and PTT. Gastric cancer Photothermal therapy Chemotherapy Magnetic nanoparticle Cisplatin Chemistry Yue Fan verfasserin aut Miaomiao Liu verfasserin aut SiLin Huang verfasserin aut Shasha Wang verfasserin aut In Arabian Journal of Chemistry Elsevier, 2016 16(2023), 7, Seite 104758- (DE-627)609401564 (DE-600)2515214-2 18785352 nnns volume:16 year:2023 number:7 pages:104758- https://doi.org/10.1016/j.arabjc.2023.104758 kostenfrei https://doaj.org/article/1891e51adc65479380b68163483747a6 kostenfrei http://www.sciencedirect.com/science/article/pii/S1878535223002204 kostenfrei https://doaj.org/toc/1878-5352 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2034 GBV_ILN_2038 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2088 GBV_ILN_2106 GBV_ILN_2110 GBV_ILN_2112 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2190 GBV_ILN_2232 GBV_ILN_2470 GBV_ILN_2507 GBV_ILN_4012 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4393 GBV_ILN_4700 AR 16 2023 7 104758-
language	English
source	In Arabian Journal of Chemistry 16(2023), 7, Seite 104758- volume:16 year:2023 number:7 pages:104758-
sourceStr	In Arabian Journal of Chemistry 16(2023), 7, Seite 104758- volume:16 year:2023 number:7 pages:104758-
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	Gastric cancer Photothermal therapy Chemotherapy Magnetic nanoparticle Cisplatin Chemistry
isfreeaccess_bool	true
container_title	Arabian Journal of Chemistry
authorswithroles_txt_mv	Dongsheng Li @@aut@@ Yue Fan @@aut@@ Miaomiao Liu @@aut@@ SiLin Huang @@aut@@ Shasha Wang @@aut@@
publishDateDaySort_date	2023-01-01T00:00:00Z
hierarchy_top_id	609401564
id	DOAJ089103653
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000naa a22002652 4500</leader><controlfield tag="001">DOAJ089103653</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230505021248.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230505s2023 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.arabjc.2023.104758</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ089103653</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ1891e51adc65479380b68163483747a6</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">QD1-999</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Dongsheng Li</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="4"><subfield code="a">The effect of using albumin-perfluorohexane/cisplatin-magnetite nanoparticles produced by hydrothermal method against gastric cancer cells through combination therapy</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2023</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Because magnetic nanoparticles (NPs) have the ability to combine different therapies such as drug delivery and photothermal therapy (PTT) along with reducing cancer drug resistance, their use in cancer treatment is considerable. For this purpose, we developed albumin-perfluorohexane/cisplatin-magnetite NPs (A-PFH/C-MNPs) by hydrothermal method. Then, the physicochemical properties of the MNPs and A-PFH/C-MNPs were investigated by SEM, TEM, XRD, and FTIR. In the following, drug release at different pH and A-PFH/C-MNPs thermal reactions were assessed. The toxicity of different drug formulations against advanced gastric cancer (AGS) and mouse fibroblast (3 T3) cells were assessed by MTT assay, followed by flow cytometry and real time PCR on AGS cells. The results determined that A-PFH/C-MNPs (∼142 nm) with a relatively uniform distribution, in addition to increasing the loading capacity up to 60%, raise the PFH release by increasing the temperature from 37 °C to 45 °C. Also, in vitro outcomes exhibited higher toxicity of A-PFH/C-MNPs + PTT compared to free C against AGS cells. Whereas, the toxicity of A-C-MNPs and A-PFH/C-MNPs + PTT on 3 T3 cells as normal cells was much lower compared to the cancer cells. The mechanism of cytotoxicity indicates that A-PFH/C-MNPs + PTT significantly increase apoptosis by inducing expression of TNF-α and Bax mRNA compared to A-C-MNPs. Overall, A-PFH/C-MNPs + PTT provided a promising platform in anticancer activity by increasing drug loading capacity and combined chemotherapy and PTT.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Gastric cancer</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Photothermal therapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Chemotherapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Magnetic nanoparticle</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cisplatin</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Chemistry</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Yue Fan</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Miaomiao Liu</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">SiLin Huang</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Shasha Wang</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Arabian Journal of Chemistry</subfield><subfield code="d">Elsevier, 2016</subfield><subfield code="g">16(2023), 7, Seite 104758-</subfield><subfield code="w">(DE-627)609401564</subfield><subfield code="w">(DE-600)2515214-2</subfield><subfield code="x">18785352</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:16</subfield><subfield code="g">year:2023</subfield><subfield code="g">number:7</subfield><subfield code="g">pages:104758-</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.arabjc.2023.104758</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/1891e51adc65479380b68163483747a6</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://www.sciencedirect.com/science/article/pii/S1878535223002204</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1878-5352</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_224</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2001</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2004</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2006</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2007</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2008</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2010</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2015</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2020</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2021</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2025</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2026</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2027</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2034</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2038</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2044</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2048</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2049</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2050</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2056</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2059</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2061</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2064</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2088</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2106</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2122</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2129</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2143</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2152</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2153</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2190</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2232</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2470</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2507</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4035</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4242</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4251</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4326</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4333</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4334</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4393</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">16</subfield><subfield code="j">2023</subfield><subfield code="e">7</subfield><subfield code="h">104758-</subfield></datafield></record></collection>
callnumber-first	Q - Science
author	Dongsheng Li
spellingShingle	Dongsheng Li misc QD1-999 misc Gastric cancer misc Photothermal therapy misc Chemotherapy misc Magnetic nanoparticle misc Cisplatin misc Chemistry The effect of using albumin-perfluorohexane/cisplatin-magnetite nanoparticles produced by hydrothermal method against gastric cancer cells through combination therapy
authorStr	Dongsheng Li
ppnlink_with_tag_str_mv	@@773@@(DE-627)609401564
format	electronic Article
delete_txt_mv	keep
author_role	aut aut aut aut aut
collection	DOAJ
remote_str	true
callnumber-label	QD1-999
illustrated	Not Illustrated
issn	18785352
topic_title	QD1-999 The effect of using albumin-perfluorohexane/cisplatin-magnetite nanoparticles produced by hydrothermal method against gastric cancer cells through combination therapy Gastric cancer Photothermal therapy Chemotherapy Magnetic nanoparticle Cisplatin
topic	misc QD1-999 misc Gastric cancer misc Photothermal therapy misc Chemotherapy misc Magnetic nanoparticle misc Cisplatin misc Chemistry
topic_unstemmed	misc QD1-999 misc Gastric cancer misc Photothermal therapy misc Chemotherapy misc Magnetic nanoparticle misc Cisplatin misc Chemistry
topic_browse	misc QD1-999 misc Gastric cancer misc Photothermal therapy misc Chemotherapy misc Magnetic nanoparticle misc Cisplatin misc Chemistry
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Arabian Journal of Chemistry
hierarchy_parent_id	609401564
hierarchy_top_title	Arabian Journal of Chemistry
isfreeaccess_txt	true
familylinks_str_mv	(DE-627)609401564 (DE-600)2515214-2
title	The effect of using albumin-perfluorohexane/cisplatin-magnetite nanoparticles produced by hydrothermal method against gastric cancer cells through combination therapy
ctrlnum	(DE-627)DOAJ089103653 (DE-599)DOAJ1891e51adc65479380b68163483747a6
title_full	The effect of using albumin-perfluorohexane/cisplatin-magnetite nanoparticles produced by hydrothermal method against gastric cancer cells through combination therapy
author_sort	Dongsheng Li
journal	Arabian Journal of Chemistry
journalStr	Arabian Journal of Chemistry
callnumber-first-code	Q
lang_code	eng
isOA_bool	true
recordtype	marc
publishDateSort	2023
contenttype_str_mv	txt
container_start_page	104758
author_browse	Dongsheng Li Yue Fan Miaomiao Liu SiLin Huang Shasha Wang
container_volume	16
class	QD1-999
format_se	Elektronische Aufsätze
author-letter	Dongsheng Li
doi_str_mv	10.1016/j.arabjc.2023.104758
author2-role	verfasserin
title_sort	effect of using albumin-perfluorohexane/cisplatin-magnetite nanoparticles produced by hydrothermal method against gastric cancer cells through combination therapy
callnumber	QD1-999
title_auth	The effect of using albumin-perfluorohexane/cisplatin-magnetite nanoparticles produced by hydrothermal method against gastric cancer cells through combination therapy
abstract	Because magnetic nanoparticles (NPs) have the ability to combine different therapies such as drug delivery and photothermal therapy (PTT) along with reducing cancer drug resistance, their use in cancer treatment is considerable. For this purpose, we developed albumin-perfluorohexane/cisplatin-magnetite NPs (A-PFH/C-MNPs) by hydrothermal method. Then, the physicochemical properties of the MNPs and A-PFH/C-MNPs were investigated by SEM, TEM, XRD, and FTIR. In the following, drug release at different pH and A-PFH/C-MNPs thermal reactions were assessed. The toxicity of different drug formulations against advanced gastric cancer (AGS) and mouse fibroblast (3 T3) cells were assessed by MTT assay, followed by flow cytometry and real time PCR on AGS cells. The results determined that A-PFH/C-MNPs (∼142 nm) with a relatively uniform distribution, in addition to increasing the loading capacity up to 60%, raise the PFH release by increasing the temperature from 37 °C to 45 °C. Also, in vitro outcomes exhibited higher toxicity of A-PFH/C-MNPs + PTT compared to free C against AGS cells. Whereas, the toxicity of A-C-MNPs and A-PFH/C-MNPs + PTT on 3 T3 cells as normal cells was much lower compared to the cancer cells. The mechanism of cytotoxicity indicates that A-PFH/C-MNPs + PTT significantly increase apoptosis by inducing expression of TNF-α and Bax mRNA compared to A-C-MNPs. Overall, A-PFH/C-MNPs + PTT provided a promising platform in anticancer activity by increasing drug loading capacity and combined chemotherapy and PTT.
abstractGer	Because magnetic nanoparticles (NPs) have the ability to combine different therapies such as drug delivery and photothermal therapy (PTT) along with reducing cancer drug resistance, their use in cancer treatment is considerable. For this purpose, we developed albumin-perfluorohexane/cisplatin-magnetite NPs (A-PFH/C-MNPs) by hydrothermal method. Then, the physicochemical properties of the MNPs and A-PFH/C-MNPs were investigated by SEM, TEM, XRD, and FTIR. In the following, drug release at different pH and A-PFH/C-MNPs thermal reactions were assessed. The toxicity of different drug formulations against advanced gastric cancer (AGS) and mouse fibroblast (3 T3) cells were assessed by MTT assay, followed by flow cytometry and real time PCR on AGS cells. The results determined that A-PFH/C-MNPs (∼142 nm) with a relatively uniform distribution, in addition to increasing the loading capacity up to 60%, raise the PFH release by increasing the temperature from 37 °C to 45 °C. Also, in vitro outcomes exhibited higher toxicity of A-PFH/C-MNPs + PTT compared to free C against AGS cells. Whereas, the toxicity of A-C-MNPs and A-PFH/C-MNPs + PTT on 3 T3 cells as normal cells was much lower compared to the cancer cells. The mechanism of cytotoxicity indicates that A-PFH/C-MNPs + PTT significantly increase apoptosis by inducing expression of TNF-α and Bax mRNA compared to A-C-MNPs. Overall, A-PFH/C-MNPs + PTT provided a promising platform in anticancer activity by increasing drug loading capacity and combined chemotherapy and PTT.
abstract_unstemmed	Because magnetic nanoparticles (NPs) have the ability to combine different therapies such as drug delivery and photothermal therapy (PTT) along with reducing cancer drug resistance, their use in cancer treatment is considerable. For this purpose, we developed albumin-perfluorohexane/cisplatin-magnetite NPs (A-PFH/C-MNPs) by hydrothermal method. Then, the physicochemical properties of the MNPs and A-PFH/C-MNPs were investigated by SEM, TEM, XRD, and FTIR. In the following, drug release at different pH and A-PFH/C-MNPs thermal reactions were assessed. The toxicity of different drug formulations against advanced gastric cancer (AGS) and mouse fibroblast (3 T3) cells were assessed by MTT assay, followed by flow cytometry and real time PCR on AGS cells. The results determined that A-PFH/C-MNPs (∼142 nm) with a relatively uniform distribution, in addition to increasing the loading capacity up to 60%, raise the PFH release by increasing the temperature from 37 °C to 45 °C. Also, in vitro outcomes exhibited higher toxicity of A-PFH/C-MNPs + PTT compared to free C against AGS cells. Whereas, the toxicity of A-C-MNPs and A-PFH/C-MNPs + PTT on 3 T3 cells as normal cells was much lower compared to the cancer cells. The mechanism of cytotoxicity indicates that A-PFH/C-MNPs + PTT significantly increase apoptosis by inducing expression of TNF-α and Bax mRNA compared to A-C-MNPs. Overall, A-PFH/C-MNPs + PTT provided a promising platform in anticancer activity by increasing drug loading capacity and combined chemotherapy and PTT.
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2034 GBV_ILN_2038 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2088 GBV_ILN_2106 GBV_ILN_2110 GBV_ILN_2112 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2190 GBV_ILN_2232 GBV_ILN_2470 GBV_ILN_2507 GBV_ILN_4012 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4393 GBV_ILN_4700
container_issue	7
title_short	The effect of using albumin-perfluorohexane/cisplatin-magnetite nanoparticles produced by hydrothermal method against gastric cancer cells through combination therapy
url	https://doi.org/10.1016/j.arabjc.2023.104758 https://doaj.org/article/1891e51adc65479380b68163483747a6 http://www.sciencedirect.com/science/article/pii/S1878535223002204 https://doaj.org/toc/1878-5352
remote_bool	true
author2	Yue Fan Miaomiao Liu SiLin Huang Shasha Wang
author2Str	Yue Fan Miaomiao Liu SiLin Huang Shasha Wang
ppnlink	609401564
callnumber-subject	QD - Chemistry
mediatype_str_mv	c
isOA_txt	true
hochschulschrift_bool	false
doi_str	10.1016/j.arabjc.2023.104758
callnumber-a	QD1-999
up_date	2024-07-03T21:16:15.231Z
_version_	1803594105074221057
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000naa a22002652 4500</leader><controlfield tag="001">DOAJ089103653</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230505021248.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230505s2023 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.arabjc.2023.104758</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ089103653</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ1891e51adc65479380b68163483747a6</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">QD1-999</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Dongsheng Li</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="4"><subfield code="a">The effect of using albumin-perfluorohexane/cisplatin-magnetite nanoparticles produced by hydrothermal method against gastric cancer cells through combination therapy</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2023</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Because magnetic nanoparticles (NPs) have the ability to combine different therapies such as drug delivery and photothermal therapy (PTT) along with reducing cancer drug resistance, their use in cancer treatment is considerable. For this purpose, we developed albumin-perfluorohexane/cisplatin-magnetite NPs (A-PFH/C-MNPs) by hydrothermal method. Then, the physicochemical properties of the MNPs and A-PFH/C-MNPs were investigated by SEM, TEM, XRD, and FTIR. In the following, drug release at different pH and A-PFH/C-MNPs thermal reactions were assessed. The toxicity of different drug formulations against advanced gastric cancer (AGS) and mouse fibroblast (3 T3) cells were assessed by MTT assay, followed by flow cytometry and real time PCR on AGS cells. The results determined that A-PFH/C-MNPs (∼142 nm) with a relatively uniform distribution, in addition to increasing the loading capacity up to 60%, raise the PFH release by increasing the temperature from 37 °C to 45 °C. Also, in vitro outcomes exhibited higher toxicity of A-PFH/C-MNPs + PTT compared to free C against AGS cells. Whereas, the toxicity of A-C-MNPs and A-PFH/C-MNPs + PTT on 3 T3 cells as normal cells was much lower compared to the cancer cells. The mechanism of cytotoxicity indicates that A-PFH/C-MNPs + PTT significantly increase apoptosis by inducing expression of TNF-α and Bax mRNA compared to A-C-MNPs. Overall, A-PFH/C-MNPs + PTT provided a promising platform in anticancer activity by increasing drug loading capacity and combined chemotherapy and PTT.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Gastric cancer</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Photothermal therapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Chemotherapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Magnetic nanoparticle</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cisplatin</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Chemistry</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Yue Fan</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Miaomiao Liu</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">SiLin Huang</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Shasha Wang</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Arabian Journal of Chemistry</subfield><subfield code="d">Elsevier, 2016</subfield><subfield code="g">16(2023), 7, Seite 104758-</subfield><subfield code="w">(DE-627)609401564</subfield><subfield code="w">(DE-600)2515214-2</subfield><subfield code="x">18785352</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:16</subfield><subfield code="g">year:2023</subfield><subfield code="g">number:7</subfield><subfield code="g">pages:104758-</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.arabjc.2023.104758</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/1891e51adc65479380b68163483747a6</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://www.sciencedirect.com/science/article/pii/S1878535223002204</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1878-5352</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_224</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2001</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2004</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2006</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2007</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2008</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2010</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2015</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2020</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2021</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2025</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2026</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2027</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2034</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2038</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2044</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2048</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2049</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2050</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2056</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2059</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2061</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2064</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2088</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2106</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2122</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2129</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2143</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2152</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2153</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2190</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2232</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2470</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2507</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4035</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4242</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4251</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4326</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4333</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4334</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4393</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">16</subfield><subfield code="j">2023</subfield><subfield code="e">7</subfield><subfield code="h">104758-</subfield></datafield></record></collection>
score	7.400383

Nicht das Richtige dabei?

Schreiben Sie uns!

The effect of using albumin-perfluorohexane/cisplatin-magnetite nanoparticles produced by hydrothermal method against gastric cancer cells through combination therapy

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?